Improved Lung Function With Cyclophosphamide and Rituximab in a Case of Shrinking Lung Syndrome

环磷酰胺和利妥昔单抗治疗肺萎陷综合征,改善肺功能

阅读:1

Abstract

Shrinking lung syndrome (SLS) is a rare respiratory complication of systemic autoimmune diseases. It is most commonly associated with systemic lupus erythematosus (SLE), often presenting as a diagnostic challenge. It is characterized by hallmark clinical features of dyspnea and pleuritic chest pain, along with radiographic evidence of reduced lung volumes and restrictive lung physiology in the absence of interstitial lung disease. Patients often demonstrate positive antibody serology due to associated underlying autoimmune conditions. In particular, anti-nuclear antibodies (ANA), low complement levels, and, in certain instances, extractable nuclear antigens (ENA) tend to be positive. We present a case of a young lady in her 20s who developed exertional shortness of breath, pleuritic chest pain, and reduced exercise tolerance. In the context of a positive autoimmune profile suggestive of SLE, typical radiological features, and pulmonary function tests, she was diagnosed with shrinking lung syndrome (SLS). The case describes therapeutic strategies that exist for the treatment of SLS, which can bring about meaningful recovery in lung function. The overall prognosis of SLS is variable, but outcomes may be favorable with timely recognition and appropriate treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。